Phase 2Phase 3RegistrationApproved in 2017 Funapide (TV-45070, Nav1.7) Neuropathic pain Fasinumab ** Chronic Lower Back Pain Laquinimod Multiple sclerosis (primary progressive) Laquinimod Huntington disease Pridopidine Huntington disease Fremanezumab (anti CGRP) Chronic migraine Fremanezumab (anti CGRP) Episodic migraine Fremanezumab (anti CGRP) Cluster Headache Fasinumab ** Osteoarthritis pain Reslizumab* SC CT-P10 *** Biosimilar(Rituxan® U.S.) CT-P6 *** Biosimilar(Herceptin® U.S.) Austedo ® Tardive dyskinesia (U.S.) QVAR® (beclomethasone diproprionate BAI) Asthma (U.S.) Reslizumab* IV Asthma (Growth Markets) Fluticasone Propionate MDPI Asthma (Growth markets) Fluticasone Salmeterol MDPI Asthma (Growth markets) Vantrela ® ER Pain (U.S.) Austedo ® Huntington Disease (U.S.) ArmonAir ® RespiClick ® Asthma (U.S.) AirDuo ® RespiClick® Asthma (U.S.)